GNI Group Ltd.(2160) News

Announcement Regarding Revision of Full-Year Earnings Forecast and Expected Recognition of Losses

GNI Group, Net Income Forecast for Last Fiscal Year Revised Downward to a Loss

Notice Concerning Completion of Acquisition of Shares (Conversion into a Consolidated Subsidiary) of ZOO LABO, Inc.

Cullgen’s Participation in the J.P. Morgan Healthcare Conference

Notice Regarding Completion of the Pre-NDA Meeting on the Regulatory Strategy for F351 Following Potential Eligibility for Priority Review

Notice Concerning Change in Consolidated Subsidiary (Termination of Equity Relationship)

Partial Amendment to Contractual Terms Relating to the Reverse Merger Transaction by Major Subsidiary Cullgen

Completion of Phase 1 Clinical Trial and Positive Results of CG001419, a Novel Non-Opioid Pain Product Candidate Developed by Key Subsidiary Cullgen

Q3 FY2025 Financial Results Corporate Presentation

GNI Group, Jan-Sep (Cumulative 3Q) Net Income Turns to Loss, Jul-Sep Net Income Decreases by 57%

Consolidated Financial Results for Q3 FY2025 YTD (IFRS)

Notice of Completion of Subject Enrollment in the Phase 3 Clinical Trial of Pirfenidone Capsule for the Treatment of Pneumoconiosis

Notice of Phase 3 Trial Results of F351 (Hydronidone) at AASLD-The Liver Meeting 2025

Notice of Completion of Subject Enrollment in the Phase 1 Clinical Trial of Novel Non-Opioid Pain Product Candidate CG001419 Developed by Key Subsidia

[Delayed]Questions from Investors and Answers

Notice Regarding Appointment of Executive Officer

[Delayed] Q2 FY2025 Financial Results Corporate Presentation

Consolidated Financial Results for Q2 FY2025 YTD (IFRS)

GNI Group, Apr-Jun (2Q) Net Income Loss Narrows

Notice Regarding Adjustment of Exercise Price, etc.